Market Trends of Apheresis Industry
This section covers the major market trends shaping the Apheresis Market according to our research experts:
Hematological Disorders Segment is Expected to Witness Significant Growth During the Forecast Period
Hematologic disorders are the disorders of blood and blood-forming organs which include problems with red blood cells, white blood cells, platelets, bone marrow, lymph nodes, and spleen. Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. As per the May 2022 update by the CDC, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Early diagnosis and treatment are the best ways to protect the life of a patient with a blood cell disorder. Hence, owing to the increasing burden of hematological incidences and growing applications of Therapeutic Apheresis as a treatment method for hematological disorders, the studied segment is expected to experience growth in the forecast period.
There has been a rise in Therapeutic Apheresis over the past few years; for instance, immunoadsorption, double filtration, and Cytapheresis are readily used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrials.gov, as of November 2022, there are 51 studies reported on Apheresis for hematological malignancy, among which about 27 studies were completed and 8 studies are currently recruiting for Apheresis and Stem Cell Collection for different hematological disease developments across the globe.
Furthermore, Apheresis has a vital role in the management of sickle cell anemia disease. As per the study published in Sage Journal in November 2021, Apheresis Equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of Apheresis in treating various hematological disorders will ultimately drive the segment growth.
North America is Expected to Witness Healthy Growth Over the Forecast Period
North America's Apheresis Market is expected to grow over the forecast period due to the growing burden of various ailments related to blood, such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels. According to the Leukemia & Lymphoma Society (LLS) 2021, approximately every three minutes, one person in the United States is diagnosed with blood cancer. The new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the total 1,898,160 new cancer cases diagnosed in the United States in 2021. The high incidence of target diseases is driving the growth of the Apheresis Market studied.
The increasing reimbursement policies in the country for Apheresis Procedures and devices are increasing the demand for Apheresis. In January 2022, United Healthcare Group issued a document UnitedHealthcare Commercial Medical Policy, which provides a medical policy for Apheresis Procedures that are performed for multiple indications except for Stem Cell Collection or harvesting for use in bone marrow/stem cell transplantation. These available policies for the procedures are increasing demand among the target population, which is ultimately driving the market for Apheresis in the country.
Furthermore, the American Society for Apheresis (ASFA) declared September 21, 2021, to be Apheresis Awareness Day, and stated that it would take place every year on the third Tuesday in September moving forward, with the next observance slated for Apheresis Awareness Day 2024. This was intended to recognize numerous donors, patients, and Apheresis professionals who have dedicated their lives to saving others by employing evidence-based practice to promote Apheresis medicine and raise awareness of Apheresis medicine. Thus, these aforementioned factors are expected to significantly boost the Apheresis Market in North America over the forecast period.
